Biolidics Overview
- Founded
-
2009

- Status
-
Public
- Employees
-
26

- Stock Symbol
-
8YY

- Investments
-
1
- Share Price
-
$0.01
- (As of Friday Closing)
Biolidics General Information
Description
Biolidics Ltd is engaged in research, experimental development, marketing, and distribution of biotechnology, life and medical science and electronics related industrial design services and investment holding. Its segments include Cancer; Infectious diseases; and Laboratory services. It derives major revenue from the infectious diseases segment that involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the infectious diseases field. Its operations are spread across Singapore, Japan, China, Europe, United States, Hong Kong, Philippines, Indonesia, and Others.
Contact Information
- 37 Jalan Pemimpin
- Number 02-07
- Mapex, 577177
- Singapore
Biolidics Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.01 | $0.01 | $0.01 - $0.09 | $6.28M | 522M | 4.98M | -$0.01 |
Biolidics Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 7,052 | 35,144 | 56,205 | 37,434 |
Revenue | 1,501 | 1,722 | 6,456 | 1,054 |
EBITDA | (2,561) | (3,409) | (2,600) | (3,135) |
Net Income | (3,587) | (4,453) | (3,371) | (3,525) |
Total Assets | 4,939 | 8,448 | 14,175 | 7,136 |
Total Debt | 2,298 | 3,142 | 3,987 | 398 |
Biolidics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Biolidics Comparisons
Industry
Financing
Details
Biolidics Competitors (8)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Standard BioTools | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000000 | 00000 |
00000 000000000000 | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
0000000 0000000000 | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000000 | 00000 |
000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
00000000 000000000 | Corporation | Mumbai, India | 00000 | 00000 | 000000000 | 00000 |
Biolidics Patents
Biolidics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-6924210-B2 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
US-11059042-B2 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
AU-2016405636-A1 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
AU-2016405636-B2 | Systems and methods for enriching target cells in a sample | Active | 04-May-2016 | 000000000000 | |
EP-3455337-A4 | Systems and methods for enriching target cells in a sample | Pending | 04-May-2016 | B01L3/502761 | 0 |
Biolidics Executive Team (13)
Biolidics Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Beng Kwan Chia | Biolidics | Board Member | 000 0000 |
Jeremy Yee | Self | Co-Chief Executive Officer & Non-Executive Non-Independent Chairman | 000 0000 |
Johnson Chen | Self | Board Member & Founder | 000 0000 |
Tony Qian | Biolidics | Board Member | 000 0000 |
Biolidics Signals
Biolidics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Biolidics Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000000 000 | 26-May-2020 | 0000000000 | 00.000 | Laboratory Services (Healthcare) |
Biolidics Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
000000000 00000000 | Laboratory Services (Healthcare) | Singapore, Singapore | 0000 |
Biolidics ESG
Risk Overview
Risk Rating
Updated February, 21, 2023
35.45 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
Percentile

Healthcare
Industry
00 of 601
Rank
Percentile

Medical Devices
Subindustry
00 of 207
Rank
Percentile
